Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2005 1
2006 1
2007 1
2010 1
2011 1
2012 5
2013 4
2014 5
2015 6
2016 8
2017 1
2019 2
2020 2
2021 4
2023 2
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Functional neurological disorder is a feminist issue.
McLoughlin C, Hoeritzauer I, Cabreira V, Aybek S, Adams C, Alty J, Ball HA, Baker J, Bullock K, Burness C, Dworetzky BA, Finkelstein S, Garcin B, Gelauff J, Goldstein LH, Jordbru A, Huys AM, Laffan A, Lidstone SC, Linden SC, Ludwig L, Maggio J, Morgante F, Mallam E, Nicholson C, O'Neal M, O'Sullivan S, Pareés I, Petrochilos P, Pick S, Phillips W, Roelofs K, Newby R, Stanton B, Gray C, Joyce EM, Tijssen MA, Chalder T, McCormick M, Gardiner P, Bègue I, Tuttle MC, Williams I, McRae S, Voon V, McWhirter L. McLoughlin C, et al. Among authors: burness c. J Neurol Neurosurg Psychiatry. 2023 Oct;94(10):855-862. doi: 10.1136/jnnp-2022-330192. Epub 2023 Mar 28. J Neurol Neurosurg Psychiatry. 2023. PMID: 36977553 Free PMC article. Review.
The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, Tudur-Smith C, Plumpton C, Hughes DA, Williamson P, Baker GA, Balabanova S, Taylor C, Brown R, Hindley D, Howell S, Maguire M, Mohanraj R, Smith PE; SANAD II collaborators. Marson A, et al. Lancet. 2021 Apr 10;397(10282):1363-1374. doi: 10.1016/S0140-6736(21)00247-6. Lancet. 2021. PMID: 33838757 Free PMC article. Clinical Trial.
Specialist physiotherapy for functional motor disorder in England and Scotland (Physio4FMD): a pragmatic, multicentre, phase 3 randomised controlled trial.
Nielsen G, Stone J, Lee TC, Goldstein LH, Marston L, Hunter RM, Carson A, Holt K, Marsden J, Le Novere M, Nazareth I, Noble H, Reuber M, Strudwick AM, Santana Suarez B, Edwards MJ; Physio4FMD study group. Nielsen G, et al. Lancet Neurol. 2024 Jul;23(7):675-686. doi: 10.1016/S1474-4422(24)00135-2. Epub 2024 May 17. Lancet Neurol. 2024. PMID: 38768621 Free article. Clinical Trial.
The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, Tudur-Smith C, Plumpton C, Hughes DA, Williamson P, Baker GA, Balabanova S, Taylor C, Brown R, Hindley D, Howell S, Maguire M, Mohanraj R, Smith PE; SANAD II collaborators. Marson A, et al. Lancet. 2021 Apr 10;397(10282):1375-1386. doi: 10.1016/S0140-6736(21)00246-4. Lancet. 2021. PMID: 33838758 Free PMC article. Clinical Trial.
Sonidegib: First Global Approval.
Burness CB. Burness CB. Drugs. 2015 Sep;75(13):1559-66. doi: 10.1007/s40265-015-0458-y. Drugs. 2015. PMID: 26323341 Review.
Anomalies in the review process and interpretation of the evidence in the NICE guideline for chronic fatigue syndrome and myalgic encephalomyelitis.
White P, Abbey S, Angus B, Ball HA, Buchwald DS, Burness C, Carson AJ, Chalder T, Clauw DJ, Coebergh J, David AS, Dworetzky BA, Edwards MJ, Espay AJ, Etherington J, Fink P, Flottorp S, Garcin B, Garner P, Glasziou P, Hamilton W, Henningsen P, Hoeritzauer I, Husain M, Huys AML, Knoop H, Kroenke K, Lehn A, Levenson JL, Little P, Lloyd A, Madan I, van der Meer JWM, Miller A, Murphy M, Nazareth I, Perez DL, Phillips W, Reuber M, Rief W, Santhouse A, Serranova T, Sharpe M, Stanton B, Stewart DE, Stone J, Tinazzi M, Wade DT, Wessely SC, Wyller V, Zeman A. White P, et al. Among authors: burness c. J Neurol Neurosurg Psychiatry. 2023 Dec;94(12):1056-1063. doi: 10.1136/jnnp-2022-330463. Epub 2023 Jul 10. J Neurol Neurosurg Psychiatry. 2023. PMID: 37434321 Review.
Idarucizumab: First Global Approval.
Burness CB. Burness CB. Drugs. 2015 Dec;75(18):2155-61. doi: 10.1007/s40265-015-0508-5. Drugs. 2015. PMID: 26578027 Review.
Omarigliptin: first global approval.
Burness CB. Burness CB. Drugs. 2015 Nov;75(16):1947-52. doi: 10.1007/s40265-015-0493-8. Drugs. 2015. PMID: 26507988 Review.
Dulaglutide: A Review in Type 2 Diabetes.
Burness CB, Scott LJ. Burness CB, et al. BioDrugs. 2015 Dec;29(6):407-18. doi: 10.1007/s40259-015-0143-4. BioDrugs. 2015. PMID: 26423061 Review.
46 results